Bill
A 2126
Requires a referenced rate for prescription drugs in New York, impacting pharmacies, PBMs, insurers, and state programs by standardizing prices for reimbursement and payments.
Overview
- Bill Number: A 2126
- Title: Relates to requiring a referenced rate for prescription drugs
- Jurisdiction: New York State Assembly (A), introduced in the 2025 session
- Status: REFERRED TO INSURANCE
- Introduced: January 15, 2025
Purpose and intent
- The bill aims to require a “referenced rate” for prescription drugs. The provided information does not include the specific mechanics or the definition of what constitutes the referenced rate, nor the context in which it would be applied (for example, to pricing, reimbursement, or state program payments). The central intent indicated by the title is to establish or mandate use of a standardized or pre-determined rate for prescription drugs.
Key provisions and changes (as available)
- Specific statutory provisions, definitions, and implementation details are not included in the provided content. Consequently, the exact procedures, the method for calculating or selecting the referenced rate, the scope (which drugs or programs are covered), and any exemptions or timelines are not specified here.
- What is known: the bill would establish or require the use of a referenced rate related to prescription drugs, which suggests changes to pricing, reimbursement, negotiation, or payment processes in the drug supply chain.
Who would be affected
- Potentially affected groups could include:
- Pharmacies and pharmacy benefit managers (PBMs)
- Insurers and health plans
- Government or state-funded programs that cover prescription drugs
- Pharmacy customers/patients
- The exact set of affected entities depends on the bill’s detailed provisions (not provided in the materials).
Procedural/timeline aspects
- Introduced: January 15, 2025
- Current status: Referred to the Assembly Committee on Insurance
- Legislative actions recorded: two entries on 2025-01-15 both indicating “REFERRED TO INSURANCE” (likely reflecting standard committee referral processes; no further actions are listed in the provided materials)
- Related bills:
- A 9086 (prior-session)
- S 1351 (companion) — listed twice as companion, indicating there are one or more Senate counterparts
Sponsorship
- Primary sponsor: Sarahana Shrestha
- cosponsors (selected examples): Judy Griffin, Angelo Santabarbara, Gabriella Romero, Jonathan Jacobson, Marcela Mitaynes, Jo Anne Simon, Linda Rosenthal, Dana Levenberg, Chris Burdick, Noah Burroughs, William Colton, Joe DeStefano, Rebecca Seawright, Zohran Mamdani, Emily Gallagher, Tony Simone, Phara Souffrant Forrest, Phil Steck, Rodneyse Bichotte Hermelyn, Steven Raga, Keith Brown, Donna Lupardo, Karines Reyes, Yudelka Tapia, Harvey Epstein, Sarah Clark (and others listed as cosponsors)
Related proposals
- A 9086 (prior-session)
- S 1351 (companion) — noted as a Senate companion
Notes for readers
- The available information does not include the bill’s full text, definitions, or the precise scope and implementation timeline. To provide a detailed, point-by-point analysis of provisions, payment mechanics, and affected programs, the full bill language or fiscal notes would be required. If you’d like, I can summarize the bill in more depth once the official text or committee memo is available.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
